Cargando…
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf®), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal...
Autores principales: | Kasper, Stefan, Kisro, Jens, Fuchs, Martin, Müller, Christian, Schulz-Abelius, Armin, Karthaus, Meinolf, Rafiyan, Mohammad-Reza, Stein, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240219/ https://www.ncbi.nlm.nih.gov/pubmed/30445951 http://dx.doi.org/10.1186/s12885-018-5063-5 |
Ejemplares similares
-
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021) -
Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021) -
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019) -
Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)